Koshino A, Oshima M, Arnott C, Fletcher RA, et al. Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis of the CREDENCE trial. Diabetes Obes Metab 2023 Jan 19. doi: 10.1111/dom.14978.
PMID: 36655422